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ApoB mRNA editing involves site-specific deamination of cytidine 6666 producing an in-frame translation stop codon. Editing minimally
requires APOBEC-1 and APOBEC-1 complementation factor (ACF). Metabolic stimulation of apoB mRNA editing in hepatocytes is associated
with serine phosphorylation of ACF localized to editing competent, nuclear 27S editosomes. We demonstrate that activation of protein kinase C
(PKC) stimulated editing and enhanced ACF phosphorylation in rat primary hepatocytes. Conversely, activation of protein kinase A (PKA) had no
effect on editing. Recombinant PKC efficiently phosphorylated purified ACF64 protein in vitro, whereas PKA did not. Mutagenesis of predicted
PKC phosphorylation sites S154 and S368 to alanine inhibited ethanol-stimulated induction of editing suggesting that these sites function in the
metabolic regulation of editing. Consistent with this interpretation, substitution of S154 and S368 with aspartic acid stimulated editing to levels
comparable to ethanol treatment in control McArdle RH7777 cells. These data suggest that phosphorylation of ACF by PKC may be a key
regulatory mechanism of apoB mRNA editing in rat hepatocytes.
© 2006 Elsevier B.V. All rights reserved.Keywords: apoB; RNA editing; APOBEC-1 Complementation factor; Phosphorylation; Regulation1. Introduction
ApoB mRNA editing occurs post-transcriptionally and
causes the site-specific deamination of cytidine 6666 to uridine
thereby creating an in-frame translation stop codon [1,2].
Consequently, two different apoB proteins are expressed, full-
length apoB100 and the truncated protein apoB48, each with
distinct physiological functions [3]. Minimally, apoB mRNAAbbreviations: APOBEC-1, apolipoprotein B editing catalytic subunit 1;
ACF, APOBEC-1 complementation factor; apoB, apolipoprotein B; RRM, RNA
recognition motif; PP1, protein phosphatase 1; PKC, protein kinase C; PKA,
protein kinase A; NT, N-terminal; CT, C-terminal
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doi:10.1016/j.bbamcr.2006.11.019editing requires the cytidine deaminase APOBEC-1 as a
homodimer [4,5], APOBEC-1 complementation factor (ACF)
[6], and the RNA substrate. Limited tissue expression of
APOBEC-1 restricts editing in humans to the small intestine
(≥85% editing), whereas in some rodents apoB mRNA editing
also occurs in the liver where it is subject to metabolic
regulation [2,3,7,8].
Under normal, physiological conditions, apoB mRNA
editing is a nuclear event occurring on spliced and polyadeny-
lated RNA [9,10]. However, in vitro editing activity could be
detected in both cytoplasmic and nuclear S100 extracts [11,12].
In vitro and in vivo data demonstrate that the proteins involved
in editing exist in two distinct complexes; active nuclear 27S
editosomes and inactive, 60S cytoplasmic complexes that can
be re-organized into active 27S complexes in vitro [11,13,14].
Proteins that form these complexes traffic between the
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ApoB mRNA editing is regulated by developmental,
hormonal, and dietary factors as well as being under tissue-
specific control [7,18–23]. Editing can be stimulated primarily
through two mechanisms: increased APOBEC-1 expression
[24] and/or through modulation of pre-existing editing factors
[25]. The fasting/refeeding and insulin induced models of
editing are associated with increased APOBEC-1 abundance
[24]. Conversely, induction of editing with ethanol was not
dependent on de novo protein or RNA synthesis [25],
suggesting modification or redistribution of pre-existing
auxiliary factors were sufficient to induce editing. In both
cases, the mechanism of induction involved the redistribution of
ACF from the cytoplasm to the nucleus [14].
Recently, ACF was shown to be a phosphoprotein in rat
primary hepatocytes [26]. The phosphorylated form was strictly
localized to nuclear 27S editing complexes, the biological site
of editing [26]. Dephosphorylation of ACF diminished in vitro
editing activity and the interaction between ACF and
APOBEC-1, but did not significantly affect RNA-binding
activity. Induction of editing by ethanol and insulin resulted in
nuclear accumulation of phosphorylated ACF [14,26] suggest-
ing that phosphorylation is a common mechanism to modulate
editing in response to metabolic stimuli. Inhibition of protein
phosphatase 1 (PP1) activity was associated with nuclear
accumulation of ACF, increased recovery of phosphorylated
ACF and robust editing levels [26]. However, the protein
kinase(s) responsible for phosphorylating ACF remain an
outstanding question.
We identified serine 154 (S154) and serine 368 (S368) as two
candidate phosphorylation sites. McArdle RH7777 cell lines
expressing S154 and S368 mutated to alanine maintained
normal basal editing levels, but these levels were refractory to
ethanol induction. Conversely, substitution of aspartic acid at
these sites significantly increased editing in the absence of
ethanol to levels comparable with those achieved by ethanol
treated cells expressing wild type ACF. The data support the
possibility that these sites are necessary for ethanol-induced
editing. Residues S154 and S368, are predicted PKC phosphor-
ylation sites, and are conserved between rat and human ACF.
Studies with PKC and PKA activators demonstrated that
modulation of PKC activity enhanced editing levels in rat
primary hepatocytes, whereas PKA did not. Similarly, purified
ACF protein was efficiently labeled by PKC isozymes, but not
by PKA. These findings are discussed in terms of structural and
functional predictions of ACF phosphorylation.
2. Materials and methods
2.1. Isolation of rat primary hepatocytes and protein kinase activator
studies
Rat primary hepatocytes were isolated from normal, fed male Sprague–
Dawley rats (Charles River Laboratories, Wilmington, MA) (250–275 g BW)
and cultured on BIOCOAT type I collagen coated, 60 mm plastic dishes (Becton
Dickinson Labware, Franklin Lakes, NJ) in Waymouth's media (Sigma
Chemical Co., St. Louis, MO) containing 0.1 nM porcine insulin (Sigma) asdescribed previously [14]. Primary hepatocytes were treated for 6 h with protein
kinase activators indolactam V, 8-cpt cAMP, and forskolin at the concentrations
encompassing their respective in vivo EC50 values, as described by the
manufacturer (Calbiochem, La Jolla, CA). Total cellular RNAwas harvested in
TriReagent (MRC, Cincinnati, OH) and processed through the poisoned-primer
extension assay to quantify the effect on apoB mRNA editing [14].
To evaluate the effect of protein kinase activation on ACF phosphorylation,
cultures were pre-incubated for 2 h with 12 or 120 μM indolactam V in
phosphate-free Waymouth's media and subsequently supplemented with 0.5
mCi 32PO4 and incubated for an additional 4 h. Cultures were harvested and
subcellular extracts prepared. ACF was immunoprecipitated, resolved by SDS-
PAGE, and specific activity was quantified as described previously [26].
2.2. Recombinant ACF purification and in vitro ACF phosphorylation
Recombinant ACF64 was expressed in E. coli and purified as described [27].
In vitro ACF labeling reactions were carried out using 2 μg of purified
recombinant ACF64 in 5 mM MgCl2, 100 μM CaCl2, 1 mM DTT, 5 μCi
32P-
γATP, 25 mM Tris–HCl pH 7.5 and 1X Lipid Activator (Invitrogen, Carlsbad,
CA) with 25 mU of each PKC isozyme (Calbiochem) or 40 mM Tris–HCl pH
7.4, 20 mM Mg Acetate, 5 μCi 32P-γATP and 25 mU of bovine PKA catalytic
subunit (Promega, Madison, WI). Reactions were incubated at 30 °C for 10 min,
terminated by acetone precipitation, resolved by 10.5% SDS-PAGE, and
transferred to nitrocellulose (Bio-Rad, Hercules, CA). Western transfers were
probed with anti-HA monoclonal antibody (Covance Research Products,
Berkeley, CA) and developed using Western Lightning reagent (NEN, Boston,
MA). 32P incorporation was monitored by phosphorimager scanning densito-
metry. PKA enzymatic activity was confirmed via labeling of Kemptide peptide
(Promega).
2.3. ACF site-directed mutagenesis and functional analysis
Rat ACF64 with a C-terminal V5 epitope tag was cloned into a modified
pcDNAIII vector (Invitrogen) [14]. ACF64 cDNA was mutated at specific
bases to convert specific serine or threonine codons to alanine or aspartic acid
codons using the QuikChange® Multi System (Stratagene, La Jolla, CA).
Mutagenic primers (T49AT50A; CCAGGCTGGGATGCTGCACCTCCT-
GAAAGGGGCTGC, T49DT50D; CCAGGCTGGGATGACGATCCTCCT-
GAAAGGGGCTGC, S132A; GGGCGTCTGTGCTGCTGTGGAC-
AACTGCCGG, S132D; GGGCGTCTGTGCTGATGTGGACAACTGCCGG,
S154A; GAGAGAAGAAATCTTGGCAGAGATGAAAAAGGTC, S154D;
GAGAGAAGAAATCTTGGACGAGATGAAAAAGGTC, S171A;
GTCATTGTCTACCCAGCCGCTGCCGATAAAACC, S171D ;
GTCATTGTCTACCCAGACGCTGCCGATAAAACC, S176A; GTCTACC-
CAAGCGCTGCTGATAAAGCCAAAAACCGGGGG, S176D; GTCTACC-
CAAGCGCTGCTGATAAAGACAAAAACCGGGGG, S188A ;
GCCTTTGTGGAATATGAAGCTCACCGCGCAGCCG, S188D;
GCCTTTGTGGAATATGAAGATCACCGCGCAGCCG, S368; CTAC-
CAAAGGACATCTCGCCAACAGAGCTCTCATCCG, S368D; CTAC-
CAAAGGACATCTCGACAACAGAGCTCTCATCCG) were extended using
PfuTurbo® DNA polymerase according to the manufacturer's recommenda-
tions. The accuracy of the mutations was verified by sequencing the entire
cDNA using T7 (Promega, Madison, WI), V5 (Sigma Genosys), and Seq481
(Sigma Genosys, The Woodlands, TX) sequencing primers (T7, TAATAC-
GACTCTATAGGG, V5; CTAGAAGGCACGTCGAGGC, Seq481; GAAC-
GAGTTGTTGATGTCATTG) and using Big Dye sequencing system (Applied
Biosystems, Foster City, CA).
McArdle RH 7777 (McArdle) cells maintained in DMEM (Gibco-BRL,
Carlsbad, CA; supplemented with 10% FBS, 10% horse serum, 1% Penicillin,
Streptomycin, Fungizone (Invitrogen)) were transfected with 2 μg plasmid
containing each ACF64 mutant using Fugene 6 (Roche, Mannheim, Germany).
Stable cell lines were created by G418 selection. When applicable, stable cell
lines were treated with 0.9% ethanol for 4 h. RNA editing of endogenous apoB
mRNA was assessed by poisoned-primer extension analysis as previously
described [14].
Expression of ACF mutants was assessed by western blotting of whole-
cell extracts prepared by lysing cells for 30 min in RIPA buffer (50 mM Tris
pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM
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Equal amounts of cell extract protein were resolved by 10.5% SDS-PAGE,
transferred to nitrocellulose, and probed with anti-V5 antibody (KPL;
Gaithersburg, MD).
McArdle RH7777 cells were transfected with pcDNA3 (Invitrogen)
containing rat ACF cDNA mutated at suspected phosphorylation sites using
FuGene6 (Roche; Basel, Switzerland). Cells were harvested 48 h post-
transfection and fractionated into nuclear and cytoplasmic fractions using the
NE-PER kit (Pierce; Rockford, IL). Lysates, 40 μg of nuclear and 60 μg of
cytoplasmic, were resolved using 8% or 10% SDS-PAGE and transferred to
nitrocellulose (BioRad, Hercules, CA). Blots were probed with anti-histone H1
(Santa Cruz Biotech; Santa Cruz, CA) and anti-actin (Sigma) to ensure proper
fractionation. Exogenous ACF was detected using anti-V5 (Invitrogen)
antibody, while both ACF populations were observed when probing with an
anti C-terminal (CT) ACF antibody [26]. To evaluate total cellular ACF
expression 60 μg of total cell lysate were resolved and probed with anti-ACF CT
antibody or actin to ensure equal loading.
2.4. Immunological techniques
Affinity purified, peptide-specific polyclonal antibodies were raised
against ACF N-terminal (NT) sequence (NHKSGDGLSGTQKE) and C-
terminal (CT) sequence (HTLQTLGIPTEGGD) in rabbits [14]; Bethyl
Laboratories, Inc., Montgomery, TX). ACF CT antibody was conjugated to
Sepharose (Bethyl Laboratories, Inc.) and ACF immunoprecipitated as
follows. Whole cell extracts were incubated with the antibody-Sepharose
bead column overnight at 4 °C. The resin was washed 3X with PBS, 1X with
10 mM phosphate buffer pH 6.8, and eluted using 100 mM glycine pH 2.5.
The eluates were neutralized with 1/10th volume 1 M Tris pH 7.5 and
precipitated with 5 volumes acetone at −80 °C. Samples were resolved by
10.5% SDS-PAGE, probed with anti-phosphoserine, threonine, or tyrosine
antibodies (Zymed Laboratories, San Francisco, CA), stripped and re-probed
with anti-ACF NT antibody.
2.5. Comparative modeling of ACF
RNA recognition motifs 1 and 2 of rat ACF64 (residues 54–223) were
aligned with RRMs 1 and 2 (residues 37–203) of human HuD protein using
ClustalX version 1.83 [28]. ACF RRM boundaries were predicted according to
alignments with existing RRM crystal structures from HuD [29], polyA binding
protein [31], and sex lethal [32]. ACF RRMs 1 and 2 were then comparatively
modeled onto the 1.8 Å crystal structure of RRMs 1 and 2 of HuD [29] using
MODELLER 6v2 [30]. Details of template assembly and utilization were as
described in the MODELLER manual. HuD and ACF ribbon diagrams were
constructed with PyMol [33]. Model quality was assessed by Ramachandran
plots using RAMPAGE [34].Fig. 1. Rat hepatic ACF immunoreactivity with anti-phosphoserine and
threonine antibodies. ACF was immunoprecipitated from liver nuclear extracts
with anti-ACF CT antibody conjugated to Sepharose and western blotted with
anti-phosphoserine, threonine, or tyrosine antibodies (right column). The blots
were stripped and re-probed with anti-ACF NTantibody. ACF, position of ACF;
anti-pSer, anti-pThr, anti-pTyr denotes position of phosphoserine, threonine, or
tyrosine immunoreactivity.3. Results
3.1. Evaluation of ACF phosphorylation
Previous studies of in vivo 32P labeling of rat primary
hepatocytes demonstrated that ACF possesses metabolically
regulated, high turnover serine phosphorylation sites [26].
However, the possibility of threonine and tyrosine phosphory-
lation at lower turnover or constitutive sites was not excluded
and thus remains a formal possibility. Rat ACF64 pro-
tein sequence was analyzed by NetPhosK (http://www.
cbs.dtu.dk/services/NetPhosK/), ProSite (http://expasy.org/
tools/scanprosite), ProteinScan (http://nci.nih.gov/MPR/
ScanProteinForPKCSitesPageaspx), and MotifScan (http://
scansite.mit.edu/motifscan_seq.phtml) algorithms for pre-
diction of potential sites of phosphorylation. The algorithmsdetected several potential serine, threonine, and tyrosine
residues with varying probabilities of being phosphorylated.
To examine the types of residues phosphorylated in ACF we
initially used an immunological approach.
ACF was immunoprecipitated from extracts of primary
hepatocytes cultured in basal insulin using immobilized ACF
CT antibody, resolved by SDS-PAGE and probed with anti-
phosphoserine, phosphothreonine, and phosphotyrosine anti-
bodies. ACF reacted with anti-phosphoserine and anti-phos-
phothreonine, but not anti-phosphotyrosine antibodies (Fig. 1,
right hand column). To confirm that phospho-ACF was
responsible for the observed immunoreactivity, western trans-
fers were stripped and re-probed with anti-ACF NT antibody
and the images overlaid (Fig. 1, left hand column). ACF and
anti-phosphoserine/threonine immunoreactivities were super-
imposed demonstrating that ACF was responsible for the
observed anti-phosphoserine/threonine reactivity.
3.2. Protein kinase activator studies
The majority of serine and threonine residues predicted to
be phosphorylated fit consensus PKC or PKA target
sequences (Table 1). Studies were therefore initiated to
evaluate the effect of PKC and PKA activation on apoB
mRNA editing in rat primary hepatocytes. Since inhibition of
PP1 stimulated editing activity [26], we reasoned that
activation of appropriate protein kinases would also induce
editing. Commercially available activators of PKC (indolactam
V, [28]) and PKA (8-cpt-cAMP [29] and forskolin [30]) were
selected for evaluation.
As anticipated, control primary hepatocytes edited 60% of
apoB mRNA and DMSO treatment did not significantly
increase editing (Table 2). Activation of PKC with 12 μM
and 120 μM indolactam V significantly stimulated editing to
92% (P≤0.01). Activation of PKA with 2 μM, 20 μM, or
200 μM 8-cpt-cAMP (EC50 2 μM) had no effect on editing
(P>0.05, Table 2) suggesting that PKA activation does not
alter editing. To exclude the possibility that 8-cpt-cAMP was
not active under our experimental conditions, we tested a
second PKA activator, forskolin. Treatment with 4 μM,
40 μM, or 120 μM forskolin also had no effect on editing
(Table 2). Furthermore, additional adenylate cyclase activa-
Fig. 2. ACF phosphorylation is modulated by protein kinase C activation. In
vivo ACF 32P incorporation was determined by Phosphorimager scanning of
ACF immunoprecipitates prepared from rat hepatocytes treated with 12 or
120 μM indolactam V (Indo V). ACF specific activity (relative to control
hepatocytes) was calculated as the ACF 32P density (Phosphorimager) divided
by the recovery of ACF determined from densitometric scanning of ACF
western blots (Image J). ACF immunopurified from control hepatocytes was
arbitrarily assigned a value of 1 (n=3). Exp. 1 and exp. 2 denote independent
experiments 1 and 2.
Table 1
Sites selected for site-directed mutagenesis
Site Sequence Average prediction percentile
T49 GGPPPGWD-T-TPPERGCE 92
T50 GPPPGWDT-T-PPERGCE 97
S132 GRLLGVCA-S-VDNCRLFV 36
S154 TKKREEIL-S-EMKKVTEG 52
S171 VVDVIVYP-S-AADKTKNR 66
T176 VVYSAADK-T-KNRGFAFV 7
S188 GFAFVETE-S-HRAAAMAR 39
S368 FPATKGHL-S-NRALIRTP 7
ACF64 protein sequence was analyzed using ProteinScan (http://mpr.nci.nih.
gov/MRP/BrowseProteins.Aspx) algorithm to predict potential PKC phosphor-
ylation sites. As an example of the range of site scoring, the average of PKC δ
and ζ percentiles are shown. The specific serine (S) or threonine (T) predicted to
be phosphorylated are shown in bold.
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(data not shown). Taken together, these data suggest that
PKC plays a role in editing regulation, while PKA does not.
In order to correlate the observed effects on editing with
changes in ACF phosphorylation, ACF was immunoprecipi-
tated from extracts isolated from hepatocytes treated with
increasing concentrations of indolactam V (Fig. 2) in the
presence of 32P. ACF phosphorylation was increased in
hepatocytes treated with 12 μM and 120 μM indolactam V.
Taken together, these data demonstrate that the cellular effects
of indolactam V that lead to enhanced editing activity are
associated with increased ACF phosphorylation.Table 2
Activation of PKC modulates apoB mRNA editing
Mean STD n
Indolactam V
Primary hepatocytes 63.3 3.9 3
DMSO 62.2 4.8 3
12 μM *92.5 0.8 3
120 μM *91.6 1.1 3
PKC EC50=μM
8-cpt cAMP
Primary hepatocytes 58.8 4.8 4
DMSO 58.2 4.6 4
2 μM 61.2 4.3 4
20 μM 59.3 (−) 2
200 μM 59.6 3.4 4
PKA EC50=2 μM
Forskolin
Primary hepatocytes 57.6 3.4 7
DMSO 61.8 4.1 6
4 μM 70.6 5.2 6
40 μM 68.5 7.5 4
120 μM 69.0 0.8 4
AC EC50=4 μM
Hepatocytes were treated with the indicated concentrations of protein kinase
activators for 6 h. ApoB mRNA editing activity was determined using apoB-
specific RT-PCR and poisoned-primer extension analysis [14]. The mean,
standard deviation (STD) and number of replicates (n) are listed below for each
concentration tested. *Statistical significance was determined to be P<0.05 by
unpaired t-test relative to DMSO control when n≥3.3.3. PKC phosphorylates ACF64
To determine if PKC can phosphorylate ACF, recombinant
rat ACF64 was expressed and purified [27] and then incubated
with equal units of various PKC isozymes or PKA catalytic
subunit. Reactions were resolved by SDS-PAGE, transferred to
nitrocellulose, and evaluated by autoradiography. Liver-
expressed PKC isozymes (including α, βII, δ, ε, and ζ;
reviewed in [31]) phosphorylated ACF64 in vitro (Fig. 3, upper
panel). To verify that the observed 32P incorporation was
specific to ACF, western transfers were probed with anti-HA
and the images overlaid (Fig. 3, lower panel). PKC isozymes α,
βII and ζ demonstrated the highest specific-activity with
ACF64. No 32P labeling was detected in the absence of protein
kinase demonstrating that the signal is PKC-dependent. These
data are consistent with the PKC activator studies (Table 2) and
suggest that liver-specific PKC isozymes are capable of
phosphorylating ACF64.
Given that ACF was predicted to contain potential PKA
phosphorylation sites, the ability of PKA catalytic subunit to
phosphorylate ACF was also evaluated. PKA catalytic subunit
was unable to phosphorylate ACF64 in vitro using the same
number of enzyme units as PKC. PKA-dependent phosphoryla-
tion of Kemptide peptide (Promega) demonstrated that the
enzyme was active under our assay conditions (data not shown).
However, 10 times greater number of units of PKA resulted in
32P incorporation into ACF (data not shown) and may represent
non-selective phosphorylation due to excess enzyme. Although
our data are consistent with phosphorylation of ACF by PKC,
we cannot rule out PKA phosphorylation since in vivoFig. 3. PKC phosphorylates ACF64 in vitro. Recombinant ACF64 was reacted
with PKC isozymes (α, βII, δ, ε and ζ) or PKA, transferred to nitrocellulose and
analyzed by autoradiography. Western transfers were subsequently probed with
anti-HA antibody. (−) denotes kinase-free control reaction only containing
buffer and ACF.
Fig. 5. Mutagenesis of predicted ACF64 phosphorylation sites modulates apoB
mRNA editing in McArdle cells. McArdle cells stably transfected with various
ACF site-directed mutants were treated with 0.9% EtOH or as control for 4 h.
RNAwas isolated, apoB RNAwas amplified and evaluated for editing using the
poisoned-primer extension assay. The central vertical line represents the level of
wild type McArdle editing. Percent change from wild type (wt) editing was
calculated by [(ACF mutant % editing−wt ACF % editing) / (wt ACF %
editing)]×100 and is shown as histograms to either side of the control value
vertical line. *Statistical significance was defined as P≤0.05 compared to
control wtACF expressing cells when n≥3. Error bars represent the calculated
standard deviation (n≥3).
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(e.g. PKA may require prior posttranslational modification of
ACF by PKC).
3.4. Site-directed mutagenesis and apoB mRNA editing
To identify candidate ACF phosphorylation sites, ACF
cDNA was selectively mutated to generate alanine or aspartic
acid at predicted PKC phosphorylation sites (Table 1). Sites
were selected for mutagenesis based on the following three
criteria: (1) ACF contains serine and threonine phosphoryla-
tion sites (Fig. 1 and [26]) predicted to be phosphorylated by
PKC (Table 1), (2) the amino terminal 380 amino acids of ACF
contain all domains necessary to complement editing includ-
ing; APOBEC-1 interaction [32], RNA-binding, [16], and a
nuclear localization sequence [33], and (3) only sites con-
served in both rat and human ACF64 were considered for our
studies (see sequence alignment Fig. 6A). We also selected
sites for mutagenesis with low and medium probabilities of
being phosphorylated (Table 1) as there are examples of
empirically determined and validated sites of phosphorylation
that were not initially predicted by consensus sequence algo-
rithms alignments [34].
Eight of the predicted sites of ACF phosphorylation were
separately mutated to either alanine or aspartic acid (Figs. 4 and
5). ApoB mRNA editing activity was evaluated in stable
McArdle cell lines that expressed similar levels of each
phosphorylation site mutants to ensured that modulation of
editing activity was not due to large differences in ACF
expression. Expression of each mutant was assessed by western
blot of whole cell extracts using an anti-V5 epitope antibody
(Fig. 4A). Cell lines were treated without or with 0.9% ethanol
for 4 h to test the ability of each mutant in ACF to support
editing activity under basal and stimulated conditions.
Editing in vector only transfected cells was indistinguishable
from control, parental McArdle cells without ethanol treatment
(data not shown). ApoB mRNA editing efficiency in wild type
McArdle cells was 14% (±4.4) (Fig. 5, shown as a vertical lineFig. 4. Expression of ACF64 site-directed mutants in McArdle cells. (A) Rat ACF64 was previously cloned [14] into modified pcDNAIII vector containing a 3′ V5
epitope tag. Equivalent number of cells and amount of protein fromMcArdle cell lines overexpressingV5-taggedACF64 constructs (as labeled) were resolved by 10.5%
SDS-PAGE, transferred to nitrocellulose and probed with anti-V5 antibody. (B) Abundance endogenous ACF is unaffected by ectopic expression of ACF64 site-
directed mutants. Whole cell extracts were generated from McArdle cells expressing ACF mutants. Equal micrograms of protein were resolved by SDS-PAGE,
transferred to nitrocellulose, and blottedwith anti-ACFCTantibody (upper panel), anti-actin (lower panel). Data shown are representative of 3 independent experiments.
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addition of ethanol significantly stimulated editing by 50%
(P≤0.05) in wild type McArdle cells (Fig. 5). A 13% (±4.4%)
increase in editing was observed in McArdle cells stably
transfected with wild type ACF64. Editing activity in ACF64
transfected McArdle cells retained the ability to respond to
ethanol stimulation (45% increase ±3.5%, P<0.05). These data
demonstrated that overexpression of ACF does not adversely
affect editing activity and that ACF64 transfected McArdle cells
responded robustly to ethanol stimulation.
There is a vast literature supporting the use of muta-
genesis to identify sites of phosphorylation. In this approach,
mimicking a phosphorylation site by mutation to aspartic
acid should induce editing in control cells, whereas ablation
of a phosphorylation site by mutation to alanine should
inhibit ethanol-induced editing. Cells transfected with an
ACF64 S154 mutated to alanine (S154A) had basal editing
values comparable to control untransfected cells. McArdle
cells expressing ACF64 S368 mutated to alanine (S368A)
demonstrated editing values only 8% (±5.0) greater than
control. In contrast, editing activity in cells transfected with
S154A or S368A had a severely blunted the response to
ethanol treatment with editing values only 10% (±7.1) and
22% (±4.4) greater than control untreated McArdle cells,
respectively (Fig. 5). These data suggested these mutants had
a dominant negative effect on the ability of the endogenous
McArdle cell machinery to respond regulated activity in
response to ethanol treatment.
Mutation of ACF64 S154 to aspartic acid (S154D)
stimulated editing 48% greater than control in the absence
of ethanol (P≤0.05). Mutation of ACF64 S368 to aspartic
acid (S368D) also enhanced editing by 48% greater than
control (P≤0.05). Treatment of McArdle cells expressing
either S154D or S368D with ethanol resulted in editing 43%
(±11.0) and 33% (±4.8) greater than control, respectively (Fig.
5). Taken together, the data suggested the phenotype of
alanine and aspartic acid mutation at S154 and S368 was
consistent with regulation of editing through these sites by
phosphorylation.
Several other serine and threonine residues were mutated
to alanine or aspartic acid, but failed to behave in a manner
consistent with regulated sites of phosphorylation. To
facilitate discussion, the remaining mutants have been
categorized as: (1) those for which mutation to alanine was
inhibitory (e.g. S171), (2) those for which mutation to
aspartic acid inhibited editing (e.g. S132), (3) those for which
ethanol treatment rescued editing of alanine and aspartic acid
mutations (e.g. S188 and T49/T50), (4) those whose editing
activity never reached wild type McArdle cell editing levels
(e.g. T176).
In the first case, cells transfected with S171 mutated to
alanine (S171A) could not maintain editing levels comparable
to cells transfected with wtACF. While these data suggest that
this site is not essential to ACF64 function and S171
phosphorylation is not critical for ethanol stimulation of editing
activity mutation of S171 to aspartic acid (S171D) stimulated
editing compared to control cells and cells transfected withwtACF. The addition of ethanol further stimulated editing in
cells expressing S171D to 40% greater than control (P≤0.05).
The data suggested that the ability of S171D to stimulate editing
activity is likely due to the change in local charge that lies close
to S154 (see structural model, Fig. 6B).
S132 was also in its own category where mutation to alanine
(S132A) displayed a phenotype similar to transfection with wild
type ACF (stimulated editing by 17% (±6.4) and 29% (±4.3) in
control and ethanol treated McArdle cells, respectively (Fig. 5).
However, mutation to aspartic acid (S132D) did not stimulate
editing activity on its own, but cells retained the ability to
respond to ethanol stimulation. The data suggest a preference
for nonpolar or uncharged amino acids at position 132 and that
ethanol treatment can activate ACF (presumably through
phosphorylation at S154 and S368 regardless of the mutations
at S132 studied here).
Mutation of S188 or T49/T50 to either alanine (S188A and
T49A/T50A) or aspartic acid (S188D and T49D/T50D)
markedly inhibited editing activity (Fig. 5). Treatment with
ethanol increased editing activity to varying levels greater
than control cell levels, but not to the extent seen in ethanol-
treated parental McArdle cells. The data suggest that S188
and T49/T50 are inherently important for ACF64 structure
and function and that it is unlikely that they are phosphoryla-
tion sites. However, consistent with phosphorylation of S154
and S368, cell lines expressing S188D or T49/T50D mutants
resulted in increased editing. Similar results were obtained
when ACF64 alanine and aspartic acid substitution mutagen-
esis was performed at S253, S274, T160 and T316 (data not
shown).
Mutation of T176 to either alanine (T176A) or aspartic acid
(T176D) resulted in the most marked dominant negative editing
phenotype (Fig. 5). With this mutation ethanol treatment was
only able to marginally restore editing to the levels, suggesting
that this site is essential as a threonine. Similar results were
obtained when ACF64 alanine and aspartic acid substitutions
were evaluated at S241, S242, S243, S377, S308, T14 and T146
(data not shown).
Our findings suggest that mutagenesis of phosphorylation
sites had an effect on ACF's ability to complement
APOBEC-1 and form functional editosomes. To rule out
the possibility that ectopically expressed ACF mutants altered
editing by changing the expression of the endogenous ACF
we evaluated the abundance of endogenous ACF in the
presence of our mutants. Irrespective of ectopic ACF64
expression, endogenous ACF abundance (normalized to
cellular actin) was not changed (Fig. 4B). The subcellular
distribution of endogenous ACF also was not significantly
changed through ectopic expression of wtACF or mutant
ACF (data not shown). These findings demonstrate that the
observed changes in editing activity are due to the properties
of individual ACF mutants.
While not exhaustive, the mutagenesis data suggested that
phosphorylation of 154, 171 and 368 would stimulate editing
activity, whereas phosphorylation at other serines or threo-
nines would markedly inhibited ACF function and editing
activity.
Fig. 6. Comparative modeling of ACF. (A) Rat and human ACF sequence alignment and secondary structure prediction. The human ACF amino acid sequence is
shown above that of rat. Black residue pairs are conserved; unique regions between ACF variants are blue and unique HuD residues are green. (*) Red letters indicate
contacts to HuD RNA. Arrows mark mutagenized residues. (B) Predicted tertiary structure of ACF and potential phosphorylation sites, provided alongside original
HuD structure bound to substrate RNA. B was made using PyMol [59].
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accessibility
The positions of ACF phosphorylation-site mutants were
evaluated based on the comparative model to HuD. This model
served to demonstrate that the predicted sites of ACF
phosphorylation might be in accessible regions of the protein.
Alignment of rat [14] and human [3] ACF64 protein sequences
demonstrated 93.5% identity (Fig. 6A). All predicted sites of
ACF phosphorylation selected for mutagenesis were conserved
between both species (Fig. 6A). HuD and ACF both contain
three RRMs and regulate mRNA stability through binding AU-
rich 3′-UTRs [17,35,39]. Alignment of the first two RRMs ofACF (residues 55–223) and HuD (37–203) maintained RNP
consensus alignment and yielded a primary sequence identity of
23%, with 57% homology. A structural model of ACF was
generated from this alignment using the 1.8 Å resolution
structure of HuD RRMs 1 and 2 bound to a short AU-rich RNA
oligomer (PDB 1FXL) [29]. These RRMs exhibited the
canonical four-stranded antiparallel β-sheet flanked by two α-
helices (Fig. 6A and B). Ninety-one percent of the modeled
ACF residues fell into favored regions of the Ramachandran
plot, with an additional 5.4% in allowed regions. Compared to
the equivalent residues in HuD, S132 of ACF is conserved
while S154, T176, and S188 are substituted with glutamine,
serine and lysine, respectively. ACF residues T49/T50 and S368
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be evaluated in this context.
In HuD, single-stranded RNA contacts the β-sheet and
surrounding loops of RRMs 1 and 2 (Fig. 6B), whereas the
flanking α-helices are more solvent exposed and therefore
accessible to protein–protein interactions (Fig. 6B and [35,36]).
It is important to note that while the position and orientation of
each residue within the modeled ACF RRMs can be evaluated,
the relative spatial orientations of each RRM cannot be deduced
without empirical structural information for ACF. Hence,
although multiple tandem RRM structures exist and the
individual RRM fold is highly conserved, the conformation of
the inter-RRM linker varies greatly among structures [37,38].
Nonetheless, since comparative modeling of a single RRM does
not rely upon knowledge of the inter-domain linker, there is
confidence that S154 resides in a solvent exposed region of the
second helix of RRM 2 (Fig. 6B). As such, the hydroxyl side
chain of this residue should be accessible to protein kinases and
phosphatases. Likewise, T176 and S171 are located within the
loop joining β-strands 2 and 3 of RRM 1 (Fig. 6B). In contrast,
S132 is located in the linker between RRMs 1 and 2, which
suggests solvent accessibility, but precludes rigorous modeling
(Fig. 6B).
4. Discussion
ApoB mRNA editing requires the coordinated assembly of a
multi-protein editosome [14] that governs substrate and site
specificity [39], the proportion of substrate edited [10] and
possibly export of the edited product from the nucleus. Thus,
regulation of editosome assembly and trafficking of editing
complexes is necessary for efficient editing. ACF is an obligate
component of the editing machinery and is the site-specific
RNA-binding protein [39,40] that docks APOBEC-1 to
cytidine 6666. Recently, phosphorylation of ACF [26] was
identified as a mechanism whereby apoB mRNA editing can be
regulated. Hyper-phosphorylation of serine residues, in active
nuclear 27S editosomes, was implicated in ethanol-stimulated
editing [26].
To better understand the role of ACF phosphorylation in
basal and metabolically stimulated editing, the sites of
phosphorylation and the enzymes responsible were character-
ized. The expression of all mutants was validated to be at similar
levels through the selection of McArdle cell lines stably
expressing each variant. While it is likely that overexpressed
wtACF or mutant ACF competed with endogenous ACF
leading to the observed changes in editing activity, the overall
abundance and subcellular distribution of endogenous ACF was
unchanged in response to ectopic expression of phosphorylation
site mutants. We have demonstrated in this report that mutation
of S154 and S368 to alanine inhibited the ability of McArdle
cells to regulate (increase) editing activity in response to
ethanol. Mutation of these residues to aspartic acid fully
stimulated editing activity even in the absence of ethanol
treatment.
S154 and S368 were predicted as phosphorylation sites,
potentially targeted by either PKA or PKC. Protein kinaseactivator studies demonstrated that only PKC activators
stimulated editing activity and enhanced ACF phosphorylation
in hepatocytes. The role of PKC in ACF phosphorylation was
further supported by in vitro protein kinase assays in which liver
expressed PKC isoforms phosphorylated recombinant ACF,
whereas PKA had to be used at 10-fold higher concentrations to
affect ACF phosphorylation. Thus our data support the role of
PKC phosphorylation of ACF64, particularly PKC isoforms α,
βII and ζ, in ethanol regulated hepatic editing activity.
Immunological data indicated that rat liver ACF possesses
both serine and threonine phosphorylation sites although only
serine phosphorylation has been observed by radiolabeling
during metabolic stimulation [26]. We believe this discrepancy
to be due to inherent differences in the experimental systems
used. Detection of phosphorylated residues by antibodies does
not require phosphate turnover (unlike metabolic labeling with
32P). These data suggest that threonine phosphorylation is
subject to slower turnover than serine phosphorylation in rat
primary hepatocytes and/or that phosphothreonine is signifi-
cantly less abundant. Our mutagenesis studies were designed to
identify sites of phosphorylation that affect ACF64 function
during metabolically stimulated editing. Given that threonine
residues were not identified in this mutagenic screen, our
collective data only support the role of regulated ACF64 serine
phosphorylation in the metabolic modulation of apoB mRNA
editing. Phosphorylated threonines are likely constitutive or
subject to slow phosphate turnover. ACF threonine phosphor-
ylation however could play an inhibitory role, by maintaining
editing at low levels under basal metabolic conditions.
Consistent with this possibility are data showing that inhibition
of protein synthesis stimulated editing in primary hepatocytes
[25]. This could be due to reduced protein synthesis of a
negative regulator of editing, such as a protein kinase active on
ACF threonines. If constitutively expressed, a protein kinase
with activity on ACF T49/T50 and T176 for example could
inhibit editing activity. The phenotype of S145D and S368D
suggested that ethanol stimulated phosphorylation of S154 and/
or S368 will override the inhibitory effects of threonine
phosphorylation and activate editing activity without necessa-
rily requiring dephosphorylation of phosphothreonine sites. We
therefore predict that at steady state hepatic ACF64 will be
phosphorylated at different sites and to varying degrees
depending on the metabolic demand. ACF containing multiple
phosphorylations was predicted by two-dimensional gel
analysis [26].
Hepatic ethanol-stimulated editing [41,42] coincides with
hyper-phosphorylation of ACF [26]. Our results demonstrate
that liver expressed PKC isozymes α, βII and ζ have the
greatest ability to phosphorylate recombinant ACF. PKC θ
overexpression has been reported to modulate editing in rat
hepatoma cells, whereas PKC isozymes α, βII, ε and ζ were
unable to modulate editing [43]. However, the authors did not
provide direct evidence that individual isoforms phosphorylated
proteins involved in editing. Moreover, PKC θ is not a
physiologically relevant isozyme since it is not expressed in
liver [44]. Further, the relative expression level of each PKC
isoform was not indicated and therefore, non-selective phos-
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by overexpression of protein kinase. In this regard, although
PKA is predicted to phosphorylate ACF and is regulated by
ethanol [45], PKA had very low activity in vitro on recombinant
ACF64 and PKA-specific activators did not modulate editing in
primary hepatocytes (Table 2). Neither direct activation of PKA
with cAMP analogs nor indirect activation via adenylate cyclase
stimulated editing. Conversely, activation of PKC with
indolactam V significantly enhanced apoB editing (Table 2)
and PKC isozymes phosphorylated purified ACF in vitro. Our
data are in agreement with results previously published
demonstrating that activation of PKC induces editing in
intestinally derived Caco-2 cells [43].
Although phosphorylated ACF has only been recovered in
the nucleus of hepatocytes, the cellular domain in which ACF is
phosphorylated remains to be determined. In vivo, PKC
substrate specificity is believed to be imparted by the
subcellular distribution of the enzyme and substrate [46].
Therefore, PKC interaction with and phosphorylation of ACF in
the perinuclear environment, at some point during nuclear
import or at some point in time subsequent to nuclear import
remain formal possibilities.
ACF is a single polypeptide that comprises three tandem
RRMs [6]. The protein itself has been implicated in apoB
mRNA-binding, APOBEC-1 binding and protection of edited
apoB mRNA from NMD [6,17]. In general, each RRM is
composed of four antiparallel β-strands flanked by two α-
helices (reviewed in [47]). RNA recognition occurs through the
β−strands and their connecting loops. Other complex embel-
lishments to the RRM fold have been documented that allow
protein–protein interactions at the α-helices [36,48,49], or β-
strands [50,51], although the nature of the ACF-APOBEC-1
interaction is unknown at present. In HuD, ssRNA makes
contact primarily to the β-sheets of RRMs 1 and 2 (Fig. 6A),
whereas the outward facing α-helices are exposed to solvent
(Fig. 6B) [35]. Based on ACF sequence homology to HuD and
the conserved structure of the RRM fold, S154 of ACF is
predicted to localize within the second helix of RRM 2, where it
would be accessible to protein kinases, but would not be
expected to contact RNA or affect RNA-binding when
phosphorylated. As such, it is plausible that this residue could
be involved in protein–protein interactions (Fig. 6A and B). The
three-dimensional model for the position and orientation of
S154 within RRM 2 is consistent with previous studies
demonstrating that treatment of extracts with calf-intestinal
alkaline phosphatase reduced co-immunopurification of APO-
BEC-1 with ACF, but did not affect ACF's ability to bind to
apoB RNA [26]. Regulation of protein–protein interactions by
changes in the phosphorylation state of one or more proteins has
been well documented [52,53]. Additionally, phosphorylation
may alter tertiary fold promoting protein–protein interactions as
is the case with CREB and CREB binding protein [54].
Another residue of interest in ACF is S171, which is a
glutamine in HuD. This residue is located in the loop between
β–strands 2 and 3 of RRM 2. Loop 3 is the most genetically
divergent region among RNP proteins and is important for
substrate specificity [47,55]. Q171 of HuD is 4 Å from the non-bridging phosphate oxygen of U5, suggesting that the
introduction of negative charge in this area could affect
substrate specificity irrespective of the phosphorylation state.
Editing activities for the S171D mutant were 15% and 28%
greater than untreated McArdle cells in the absence and
presence of ethanol, respectively. The introduction of negative
charge by aspartic acid mutation in S171D may have
contributed to the slight elevation in editing activity, but the
data suggest that it is unlikely that S171 is an ethanol regulated
phosphorylation site.
Our mutagenesis analyses predicted that some serine/
threonine residues in and of themselves are important for
ACF structure and also editing. The introduction or ablation of
negative charge at these residues could affect protein folding,
protein–protein interactions, protein–RNA interaction and thus
function independent of protein phosphorylation. In this case,
mutagenesis of these sites to alanine and aspartic acid would
disrupt editing. Case in point, S132 is conserved in rat and
human ACF as well as in HuD and is located in between RRMs
1 and 2. The data suggested that mutation to alanine at this site
was tolerated since editing was comparable to wild type ACF64.
However, mutation to aspartic acid was detrimental. Although
serine residues are polar, the R group is uncharged at pH 7.0.
Mutation to alanine, a nonpolar amino acid, with only a methyl
moiety as the R group would be less likely to interfere with
protein folding. To the contrary, substitution with negatively
charged aspartic acid could alter protein folding. Therefore,
S132 is unlikely to be a phosphorylation site.
Limited structural information precludes modeling outside of
ACF RRMs 1 and 2. Consequently, mutations amino terminal to
amino acid 55 (e.g. T49/T50) and those carboxy terminal to
amino acid 223 (e.g. S368) cannot be evaluated in the context of
this model. However, S368 is located within ACF's nuclear
localization sequence (amino acids 360–401) [33]. ACF is a
nucleocytoplasmic shuttling protein related to hnRNP proteins
[33] and its subcellular distribution is sensitive to metabolic
perturbations [33]. Significantly, phospho-ACF accumulates in
the nucleus of hepatocytes treated with ethanol or insulin [14].
The S368 to alanine mutation was refractory to ethanol, whereas
the aspartic acid mutation stimulated editing in untreated
McArdle cells to levels comparable to cells treated with ethanol.
These data suggest that phosphorylation of S368 may modulate
ACF nucleocytoplasmic shuttling. In fact, several examples
exist in the literature where phosphorylation mediated nuclear
localization ([53,56,57] reviewed in [58]). The coordinated
action of protein phosphatase I [26] and PKC could regulate that
subcellular distribution of ACF, and therefore the proportion of
apoB mRNA that is edited.
In conclusion, the data suggest a model of editing regulation
in McArdle cells whereby ACF is phosphorylated minimally on
serine and threonine residues in basal McArdle cells. Metabolic
stimulation of editing by ethanol may be accompanied by
phosphorylation of S154 and S368 by PKC. Protein phospha-
tase 1 activity has been implicated in removing phosphate from
metabolically regulated sites of ACF phosphorylation, enhan-
cing export of ACF from the nucleus [26] and reducing editing
activity. Our findings suggest that phosphorylation of ACF by
417D.M. Lehmann et al. / Biochimica et Biophysica Acta 1773 (2007) 408–418PKC in response to ethanol is part of the mechanism for nuclear
import of ACF and activation of editing activity. In this regard,
PKC and PP1 activities on ACF are predicted to act in concert to
modulate the overall phosphorylation status of ACF, regulating
its protein interactions and subcellular distribution.
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